AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June...